MarketInOut Stock Screener Log In | Sign Up
 

Astellas Pharma Inc ADR

OTC • Healthcare • Drug Manufacturers - General • Quote as of 05/13/2026 16:00
Astellas Pharma Inc ADR stock price and volume chart

Company Profile

IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeOTC
Market Capitalization26,281 mln
Float1,791 mln
Earnings Date04/27/2026

EPS

1.04
Decent

P / E

14.46
Fair value

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-2.46
Borderline

1-Year Forecast

19.00
Strong upside

Relative Strength

68 / 100
Outperforming

Business Description

Astellas Pharma is a Japan-based pharmaceutical company that develops and sells medicines for serious conditions including prostate cancer, leukemia, kidney disease, and menopause-related symptoms, among others. The company serves patients across oncology, urology, ophthalmology, immunology, and women's health, distributing its products both domestically and around the world. Astellas also works with external partners to advance new treatment approaches, including RNA-based therapies and diabetes management tools. Founded in 1923 and headquartered in Chuo, Japan, the company has built a broad portfolio of specialty medicines over its century-long history.

Key Fundamentals

EPS1.04
P/E14.46
ROE20.59
RPS7.68
ROIC10.58
ROA9.42
Interest Cover26.09
EBITDA, mln3,983
EV / EBITDA7.65
EV / EBIT11.30
Revenue, mln13,792
EV / Revenue2.21

Financial Strength

Altman Z-Score2.81
Piotroski F-Score 7 / 9
Beneish M-Score-2.46
Price to Intrinsic Value1.11
Price to Lynch Fair Value1.89
Price to Graham Number2.86
1-Year Target Price19.00
Shiller PE Ratio26.67

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 4.74% 74 / 100   
1 Month -6.12% 27 / 100   
2 Months -2.15% 45 / 100   
6 Months 31.81% 72 / 100   
1 Year 59.32% 71 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us